secwatch.observer — SEC 8-K summary
======================================

Issuer:     Keenova Therapeutics plc (—)
CIK:        0001567892
Form:       8-K
Filed at:   2024-12-05T23:59:59+00:00
Accession:  0001567892-24-000045
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 2.01, 2.04, 1.01, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mallinckrodt completes Therakos sale, uses $887.6M net proceeds to cut net debt >60%
--------------------------------------------------------------------------------

- Closed Therakos divestiture for $925M base; net cash $887.6M after working capital adjustments.
- Mandatory debt prepayment on Dec 6: ~$474.1M term loans ($36.4M makewhole) and ~$301.4M notes ($27.3M makewhole).
- Total principal reduction ~$775.5M; net debt expected to fall more than 60%.
- Board adopted Second A&R Transaction Incentive Plan; bonus pool capped at 3% of transaction proceeds.
- PSU award agreements amended to convert to time-vested upon a Qualifying Significant Event.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1567892/000156789224000045/0001567892-24-000045-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1567892/000156789224000045/mnk-20241129.htm
  HTML page:      https://secwatch.observer/filing/0001567892-24-000045

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer